Showing results (91-100 of 295) with videos related to
Sort By:
Pageof 30
Journal of Biomolecular Screening|November 10, 2006
Identification of novel keratinocyte differentiation modulating compounds by high-throughput screeningMasaru Honma, Mark Stubbs, Ian Collins, et al.Cell Chemical Biology|June 2, 2021
Evolution of kinase polypharmacology across HSP90 drug discoveryAlbert A Antolin, Paul A Clarke, Ian Collins, et al.Anticancer Research|August 15, 2002
ErbB2 overexpression in an ovarian cancer cell line confers sensitivity to the HSP90 inhibitor geldanamycinVicki Smith, Stephen Hobbs, William Court, et al.Molecular Cancer Research : MCR|July 30, 2015
Maximizing the Therapeutic Potential of HSP90 InhibitorsLisa M Butler, Roberta Ferraldeschi, Heather K Armstrong, et al.Cancer Research|February 25, 2010
Drugging the PI3 kinome: from chemical tools to drugs in the clinicPaul Workman, Paul A Clarke, Florence I Raynaud, et al.Frontiers in Immunology|February 29, 2024
Manipulating the tumor immune microenvironment to improve cancer immunotherapy: IGF1R, a promising targetMarsha Pellegrino, Valerio Secli, Silvia D'Amico, et al.Cancer Research|December 3, 2005
Activated B-RAF is an Hsp90 client protein that is targeted by the anticancer drug 17-allylamino-17-demethoxygeldanamycinSilvy da Rocha Dias, Frank Friedlos, Yvonne Light, et al.Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|January 22, 2003
Validation of liquid chromatography assay for the quantitation of (Z)-3-[2,4-dimethyl-5-(2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-1H-pyrrol-3-yl]propionic acid (SU006668) in human plasma and its application to a phase I clinical trialYasmin Asad, Gillian Cropp, Alison Adams, et al.Molecular Cancer Therapeutics|September 20, 2005
An evaluation of the ability of pifithrin-alpha and -beta to inhibit p53 function in two wild-type p53 human tumor cell linesMike I Walton, Stuart C Wilson, Ian R Hardcastle, et al.Cancer Discovery|September 15, 2023
Which Small Molecule? Selecting Chemical Probes for Use in Cancer Research and Target ValidationMary M Mader, Joachim Rudolph, Ingo V Hartung, et al.Pageof 30